Stefania Capone

TL;DR: It is demonstrated that vaccines developed with adenoviral vectors can induce broad and sustained immune responses to HCV in humans and open the way for studies of prophylactic and therapeutic vaccines for HCV.

TL;DR: The findings show that it is possible to elicit effective immunity against heterologous HCV strains by stimulating only the cellular arm of the immune system, and suggest a path for new immunotherapy against highly variable human pathogens like HCV, HIV or malaria, which can evade humoral responses.

TL;DR: A first-in-human trial of a prime-boost vaccine strategy for HCV, with durable, broad, sustained, and balanced T cell responses, characteristic of those associated with viral control, paving the way for the first efficacy studies of a prophylactic HCV vaccine.

TL;DR: It is shown that rare serotypes of human adenoviruses, which should not be neutralized in most humans, are far less potent as vaccine vectors than Ad5 in mice and nonhuman primates, casting doubt on their potential efficacy in humans.

TL;DR: An improved genetic immunization strategy for eliciting a full spectrum of anti-hepatitis C virus (HCV) envelope 2 (E2) glycoprotein responses in mammals through electrical gene transfer (EGT) of plasmid DNA into muscle fibers potentially provides a safe, low-cost treatment that may be scaled up to humans.